PYC Therapeutics (ASX:PYC) said that the safety review committee monitoring the single ascending dose study of its drug candidate PYC-001 for patients with autosomal dominant optic atrophy approved an increase in the dose, according to a Wednesday Australian bourse filing.

The committee approved an increase in the dose to be administered to patients in groups two and three to 30 micrograms per eye from 10 micrograms, following an evaluation of four-week follow-up data.

The study will be followed by a multiple ascending dose study and an open-label extension study, facilitating repeat dosing and the evaluation of the optimal dosing regimen, safety, tolerability, and efficacy profile.

The company's shares shed 1% in recent Wednesday trade.